DEFA14A: Vanda Pharmaceuticals Clarifies Director Retention Amidst Shareholder Vote Controversy and Rights Agreement Lapse

Vanda Pharmaceuticals Inc. has issued a proxy supplement to explain its Board's decision to retain director Phaedra Chrousos despite her failure to receive a majority vote at the 2024 Annual Meeting, while also confirming the expiration of a controversial Rights Agreement.

Summary

• Vanda Pharmaceuticals Inc. filed a proxy statement supplement on May 27, 2025, for its Annual Meeting of Stockholders on June 5, 2025.
• The supplement clarifies the Board's decision to retain director Phaedra Chrousos, who failed to receive a majority of votes cast for her re-election at the 2024 Annual Meeting of Stockholders.
• Ms. Chrousos tendered a conditional resignation, which the Nominating/Corporate Governance Committee and the full Board unanimously voted to decline on May 22, 2024.
• The Board's rationale for retaining Ms. Chrousos included the small margin of her vote failure, the fact that the company's largest stockholder (representing approximately 15% of outstanding shares) voted for her, her extensive qualifications and experience, her past and expected future contributions, the overall Board composition, and the difficulty of finding a timely replacement.
• The Company believes Ms. Chrousos's vote failure was primarily due to a proxy advisory firm's recommendation against her re-election, linked to the Board's adoption of a Rights Agreement on April 17, 2024.
• The Rights Agreement, which was unanimously adopted by the Board, expired on April 16, 2025, and the Board decided to let it lapse rather than renew it after engaging with stockholders.
• The Company engaged with stockholders in late 2024 and early 2025, including its largest stockholder, who expressed concerns about the Rights Agreement but not about Ms. Chrousos's qualifications or retention.
• The Board continues to recommend a vote 'For' its two director nominees at the upcoming 2025 Annual Meeting.

Sentiment

Score: 5

Explanation: The document addresses a negative governance event (failed director re-election) but outlines the Board's rationale for retention and its subsequent actions (lapse of Rights Agreement, shareholder engagement) to mitigate concerns. This indicates a neutral to slightly positive effort to resolve a contentious issue, but the underlying negative vote remains.

Positives

• The Board engaged in discussions with stockholders, including its largest stockholder, to address concerns regarding corporate strategy and the Rights Agreement.
• The controversial Rights Agreement, which was a point of contention with proxy advisory firms and some institutional investors, was allowed to lapse upon its expiration on April 16, 2025, demonstrating responsiveness to shareholder feedback.
• The company's largest stockholder, representing approximately 15% of outstanding shares, voted in favor of Ms. Chrousos, indicating significant institutional support despite the overall vote outcome.
• The Board provided a detailed rationale for retaining Ms. Chrousos, emphasizing her qualifications, experience, and anticipated contributions, which could be seen as a commitment to board stability and expertise.

Negatives

• Director Phaedra Chrousos failed to receive a majority of the votes cast for her re-election at the 2024 Annual Meeting of Stockholders, indicating a significant level of shareholder dissatisfaction.
• The failure to secure a majority vote was attributed to a proxy advisory firm's recommendation against Ms. Chrousos, specifically due to her role as chair of the Nominating/Corporate Governance Committee at the time of the adoption of the Rights Agreement.
• The initial adoption of the Rights Agreement on April 17, 2024, generated sufficient controversy to influence institutional investor voting against a director, highlighting a potential misalignment with shareholder interests at that time.

Risks

• Potential for continued shareholder scrutiny or activism regarding corporate governance practices, particularly concerning board independence and responsiveness to shareholder votes, despite the lapse of the Rights Agreement.
• Risk of negative perception among some investors due to the Board's decision to override a majority 'against' vote for a director, which could be seen as undermining shareholder democracy.
• Difficulty in attracting and retaining independent directors if the company faces ongoing governance challenges or if board decisions are perceived as not fully aligned with shareholder interests.

Future Outlook

The Board continues to recommend a vote 'For' each of its two director nominees at the upcoming 2025 Annual Meeting, indicating a desire for continuity and stability in its governance structure. The lapse of the Rights Agreement suggests a more shareholder-friendly approach moving forward.

Management Comments

• "The Company decided to file this proxy supplement after being notified of the contents of a proxy advisory firms voting recommendation report, which necessitated the clarification of the public record in the interests of accuracy."
• "The Committee considered Ms. Chrousos conditional resignation and recommended that the Board reject her conditional resignation."
• "The Board determined that the resignation of Ms. Chrousos would be detrimental to, and not in the best interests of, Vanda and its stockholders."
• "Vanda believes that Ms. Chrousos receiving the support of less than a majority of the votes cast for her election was not related to her performance, but rather was related to a proxy advisory firms recommendations regarding a Rights Agreement..."
• "The Board believes that its two director nominees are deserving of re-election and continues to recommend a vote For each of the nominees at the Annual Meeting."

Industry Context

This announcement reflects ongoing tensions between corporate boards and institutional investors regarding corporate governance, particularly around shareholder rights plans (poison pills) and director accountability. The influence of proxy advisory firms on voting outcomes remains significant. Companies are increasingly expected to engage proactively with shareholders on governance matters, especially following adverse voting results, to maintain investor confidence and avoid further activism.

Comparison to Industry Standards

• The company's Corporate Governance Guidelines include majority voting and advance resignation provisions, which align with best practices for director accountability, though the Board's decision to override the majority vote for Ms. Chrousos deviates from the direct outcome of that standard.
• The Board's engagement with its largest stockholder and subsequent decision to let the Rights Agreement lapse demonstrates a degree of responsiveness to shareholder concerns, a practice increasingly expected of public companies, similar to how other companies might adjust policies after shareholder pressure (e.g., Apple's response to shareholder proposals on executive compensation or ExxonMobil's engagement with Engine No. 1 on climate strategy).
• The controversy surrounding the Rights Agreement and its impact on director votes is a common theme in corporate governance, with many companies facing similar challenges when adopting or extending such defensive measures (e.g., Papa John's International's adoption of a poison pill in 2018 or Barnes & Noble's in 2011, often leading to proxy advisor opposition).

Corporate Governance

Stakeholder Impact

• **Shareholders**: The document directly addresses shareholder concerns regarding director accountability and the Rights Agreement, aiming to clarify the Board's actions and maintain confidence. The lapse of the Rights Agreement is likely positive for shareholder rights.
• **Board of Directors**: The Board's decision to retain Ms. Chrousos highlights its commitment to its chosen leadership and strategic direction, but also its responsiveness to shareholder feedback by letting the Rights Agreement expire.
• **Proxy Advisory Firms**: The document directly references and responds to a proxy advisory firm's recommendation, indicating the significant influence these firms have on corporate governance and voting outcomes.

Next Steps

• The 2025 Annual Meeting of Stockholders is scheduled for June 5, 2025, where stockholders will vote on director nominees and other proposals.
• Ms. Chrousos will continue to serve as a director until Vanda's 2027 annual meeting of stockholders or until her successor is duly elected and qualified, or until her prior death, resignation, retirement, disqualification or other removal.

Key Dates

Recommendation

Keywords

Vanda Pharmaceuticals, SEC filing, Proxy Statement, Corporate Governance, Director Election, Shareholder Vote, Rights Agreement, Board of Directors, Proxy Advisory Firm, Stockholder Engagement, DEFA14A